Activity

Cesium and molybdenum are fission products of uranium dioxide fuel in nuclear reactors, which interact with each other depending on the oxygen potential of the fuel. This leads to formation of various compounds of the Cs

O-MoO

system, which are exposed to high temperatures during operation of a reactor or a severe accident at a nuclear power plant. This is why the study of the vaporization and thermodynamics of compounds in the Cs

O-MoO

system is important.

Synthesis of the compounds in the Cs

O-MoO

system was carried out by sintering Cs

MoO

and MoO

. Characterization of the samples was accomplished with the use of XRD, TGA/DSC/DTA, IR spectroscopy, and ICP emission spectroscopy. Vaporization of the samples under study was carried out from a platinum effusion cell using an MS-1301 mass spectrometer developed for high-temperature studies of low-volatility substances.

The temperature dependences of partial pressures of vapor species were determined over pure MoO

and Cs

MoO

in the ranges 870-1000 K and 1030-1198 K, respectively. MoO

, Mo

O

, Mo

O

, Mo

O

, and Mo

O

were shown to be the main vapor species over the Cs

O-MoO

system in the temperature range 850-1020 K. The component activities, Gibbs energies of mixing, and excess Gibbs energies were obtained as functions of the component concentration at 900, 950, and 1000 K.

The thermodynamic properties of the Cs

O-MoO

system found in the study evidenced negative deviations from ideality. The MoO

and Cs

MoO

partial molar enthalpies of mixing, the Cs

MoO

partial vaporization enthalpy, and the total enthalpy of mixing in the Cs

O-MoO

system at 1000 K were obtained for the first time.

The thermodynamic properties of the Cs2 O-MoO3 system found in the study evidenced negative deviations from ideality. The MoO3 and Cs2 MoO4 partial molar enthalpies of mixing, the Cs2 MoO4 partial vaporization enthalpy, and the total enthalpy of mixing in the Cs2 O-MoO3 system at 1000 K were obtained for the first time.The use of magnetic fields in the intermediate-frequency (IF) range to wirelessly charge electric cars with power transfer in the kilowatt range has become increasingly widespread, leading to unavoidable stray fields in the microtesla range. Only a handful of studies have assessed the potential biological risks associated with exposure to such fields. We exposed female mice (n = 80 per group) to either 20 kHz, 360 µT (rms), or sham in Helmholtz coils to conduct a blind design study. Exposure started at 3 months of age (24 h/day). Body mass was recorded every 1-2 weeks. At 10 months of age, three behavioral tests were performed on 24 animals per group. Three months later, the mice were sacrificed and organs (brain, liver, kidney, spleen, and lung) were removed and prepared for microscopic analysis. Our findings demonstrate no differences in the development of body mass and survival rates (96% and 89%, respectively). Similarly, no significant differences were observed in tumor incidence rates. When it comes to behavioral tests, the 8-arm maze results revealed no significant differences. In contrast, the Rotarod data were significantly (P  less then  0.001) different with longer retention times seen in the exposed mice. In the open field, the number of supported rears was significantly lower (P  less then  0.01), whereas the other endpoints did not show any differences. Overall, our data reveal no adverse effects of exposure to 20 kHz, 360 µT on the development and tumor incidences, while the significant differences in the behavioral tests may indicate higher levels of alertness in mice.Two new aqueous UIV complexes were synthesized by the interaction between the tetravalent uranium cation and the (1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetra(methylene phosphonic acid) (DOTP) macrocyclic ligand. Two distinct homonuclear complexes were identified; the first was characterized by X-ray crystallography as a unique “out-of-cage”, [U(DOTPH6 )2 ] complex, in which the UIV cation is octa-coordinated to 4 phosphonic arms from each ligand in a square anti-prism geometry, with a C4 symmetry. The second is the “in-cage” [U(DOTPH4 )] complex, in which the tetravalent cation is located between the macrocycle O4 and N4 planes. With the help of UV-Vis absorption, 1 H/31 P NMR, ATR-IR, and MALDI-TOFMS analytical techniques, the chemical interchange between both species is presented. It is shown that the one-way transition is governed by the formation of a multiple number of soluble oligomeric species consisting of varied stoichiometric ratios of both characterized homonuclear complexes.Postoperative chylous ascites is a rare but highly morbid complication following thoracic or abdominal surgeries. Treatment options vary according to different clinical scenarios and facility equipment, but there is no standard guideline. We report a case of 46-year-old patient with chylous ascites after left laparoscopic adrenalectomy for metastatic lung cancer. The conservative treatments failed, included diet control, somatostatin provided and intranodal lymphangiography with lipiodol injection. Laparotomy was performed to explore the lymphatic vessel in the retroperitoneal area where a major and several small leaking holes were identified along the thoracic duct. The left gonadal vein was explored and transposed toward the lymphatic vessel. The lymphaticovenous anastomosis (LVA) was done using side (major leaking hole) to end (gonadal vein) fashion. The chylous leakage dropped from 2000 to 200 mL per day gradually within 10 days after LVA, and the patient was discharged uneventfully 30 days after the LVA surgery. He was followed at our clinic during the first postoperative 10 months without recurrent chylous ascites. This case demonstrates that microsurgical intervention with LVA to physiologically drain the chyle can be an optimal treatment for chylous ascites. GSK-3484862 nmr A literature review was also conducted, and strategic management is proposed.

To evaluate pharmacokinetic equivalence and preliminary safety of the adalimumab biosimilar CT-P17 administered via autoinjector (CT-P17 AI) or prefilled syringe (CT-P17 PFS) in healthy subjects.

This phase I, open-label study (ClinicalTrials.gov NCT04295356) randomised subjects (11) to receive a single 40-mg (100 mg/mL) dose of CT-P17 AI or CT-P17 PFS. Primary endpoint was pharmacokinetic equivalence of CT-P17 AI to CT-P17 PFS for area under the concentration-time curve from time zero to infinity (AUC

); area under the concentration-time curve from time zero to the last quantifiable concentration (AUC

); maximum serum concentration (C

). Equivalence was determined if the 90% confidence interval for the geometric least-squares mean ratio was within the 80-125% equivalence margin. Additional pharmacokinetic endpoints, safety and immunogenicity were evaluated.

Of 193 subjects who were randomised (98 CT-P17 AI; 95 CT-P17 PFS), 180 received study drug. Pharmacokinetic equivalence was demonstrated 90% confidence intervals were within the 80-125% equivalence margin (AUC

93.